EFFICACY OF VENETOCLAX plus OBINUTUZUMAB plus IBRUTINIB COMPARED TO ALTERNATIVE THERAPEUTIC OPTIONS IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (FIT POPULATION): A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS

被引：0
|
作者：
Stozek-Tutro, A. [1 ]
Reczek, M. [2 ]
Kawalec, P. [3 ]
机构：
[1] Jagiellonian Univ, Doctoral Sch Med & Hlth Sci, Med Coll, Crocow, MA, Poland
[2] HTA Consulting, Krakow, Poland
[3] Jagiellonian Univ, Inst Publ Hlth, Med Coll, Krakow, Poland
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO182
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [41] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (vol 20, pg 43, 2019)
    Moreno, C.
    Greil, R.
    Demirkan, F.
    LANCET ONCOLOGY, 2019, 20 (01): : E10 - E10
  • [42] Efficacy and Safety of Various First-Line Therapeutic Strategies for Fetal Tachycardias: A Network Meta-Analysis and Systematic Review
    Qin, Jiangwei
    Deng, Zhengrong
    Tang, Changqing
    Zhang, Yunfan
    Hu, Ruolan
    Li, Jiawen
    Hua, Yimin
    Li, Yifei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [43] COST-MINIMIZATION AND BUDGET IMPACT ANALYSIS OF VENETOCLAX PLUS OBINUTUZUMAB COMPARED WITH ACALABRUTINIB IN THE FIRST LINE AND R/R CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE
    Marinato, A.
    Takao, A.
    Campos, L.
    Silva, R.
    Tanaka, S.
    VALUE IN HEALTH, 2022, 25 (12) : S126 - S127
  • [44] Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
    Jain, Nitin
    Croner, Lisa J.
    Allan, John N.
    Siddiqi, Tanya
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Eckert, Karl
    Cheung, Leo W. K.
    Mukherjee, Anwesha
    Dean, James P.
    Szafer-Glusman, Edith
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2024, 30 (03) : 498 - 505
  • [45] Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
    Zhang, Yiyin
    Xu, Jin
    Hua, Jie
    Liu, Jiang
    Liang, Chen
    Meng, Qingai
    Ni, Quanxing
    Shi, Si
    Yu, Xianjun
    JOURNAL OF CANCER, 2019, 10 (18): : 4420 - 4429
  • [46] EFFICACY AND SAFETY OF OXALIPLATIN/CAPECITABINE BASED CHEMOTHERAPY PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT FOR ADVANCED COLORECTAL CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Dang, A.
    Likhar, N.
    Vsn, M.
    Hyderboini, R. K.
    Inuganti, A.
    Thode, R.
    Sirumalla, Y.
    Sharma, A.
    Ghosh, S.
    VALUE IN HEALTH, 2017, 20 (05) : A91 - A92
  • [47] Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis
    Terasawa, Teruhiko
    Trikalinos, Nikolaos A.
    Djulbegovic, Benjamin
    Trikalinos, Thomas A.
    CANCER TREATMENT REVIEWS, 2013, 39 (04) : 340 - 349
  • [48] First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis
    Ciliberto, Domenico
    Carid, Giulio
    Staropoli, Nicoletta
    Romeo, Caterina
    Arillotta, Grazia Maria
    Napoli, Cristina
    Gervasi, Luigia
    Luciano, Francesco
    Riillo, Caterina
    Tassone, Pierfrancesco
    Tagliaferri, Pierosandro
    HELIYON, 2023, 9 (08)
  • [49] Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an OpenLabel Phase II Study
    Hillmen, Peter
    Gribben, John G.
    Follows, George A.
    Milligan, Donald
    Sayala, Hazem A.
    Moreton, Paul
    Oscier, David G.
    Dearden, Claire E.
    Kennedy, Daniel B.
    Pettitt, Andrew R.
    Nathwani, Amit
    Varghese, Abraham
    Cohen, Dena
    Rawstron, Andy
    Oertel, Stephan
    Pocock, Christopher F. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (12) : 1236 - +
  • [50] First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    Chen, Kang-Kang
    Du, Tai-Feng
    Wu, Ku-Sheng
    Yang, Wei
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3891 - 3910
12345